Is Thymosin Alpha-1 Legal in Missouri? How to Access It Legally
HealthRX.com
Thymosin alpha-1 has no FDA-approved US product to access
Key numbers
- 4 yes and 17 noVotes by FDA's Pharmacy Compounding Advisory Committee on thymosin alpha-1 for compounding, 4 December 2024Source: fda.gov, as cited Nov 7, 2026
- 1.6 mgDose in the Italian Zadaxin label for the finished injection, not a US dose or a compounded productSource: fda.gov, as cited Nov 7, 2026
- 1,349 adultsAdults in the 2026 Cochrane review of thymosin alpha-1 trials, with low-certainty evidence on benefitSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None. Four US orphan drug designations, which are not approvals [1]
- FDA list, state-licensed pharmacies / In none of the three categories; category 1 policy does not apply [2]
- FDA list, outsourcing facilities / Category 3, 'nominated without adequate support' [5]
- FDA advisory vote / 4 yes, 17 no, 4 December 2024 [6]
- HHS peptide draft policy / Not one of the six peptides named [3]
- FDA safety concerns / Immunogenicity and peptide-characterisation concerns still posted [7]
- Missouri telehealth / Provider must be fully licensed in Missouri [4]
- Sport / Not named on WADA's 2026 Prohibited List [8]
What is thymosin alpha-1 and where is it approved?
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract. Thymalfasin is the synthetic version with the same sequence. Zadaxin is the brand of the finished injection sold outside the US at 1.6 mg per vial, and it is not interchangeable with bulk thymosin alpha-1 powder [1].
Thymosin alpha-1 is not FDA-approved; FDA's search of Drugs@FDA found no US application for it. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process and is not an approval [1].
That same review lists national authorisations in Italy, where Zadaxin is authorised as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and in Hong Kong [1]. Two older reviews by authors tied to the Zadaxin developer say it is approved in over 35 countries (2009) and more than 30 countries (2007) [9][10]. FDA could not independently verify those broader regional claims, and the European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
Where does thymosin alpha-1 sit on FDA's compounding lists?
FDA says compounded drugs are not FDA-approved, so FDA does not review them for safety, effectiveness or quality before they reach patients [11]. FDA keeps lists of the bulk substances that may be used in compounding.
On FDA's list for state-licensed pharmacies and physicians, updated 14 May 2026, thymosin alpha-1 appears in none of the three categories, and FDA's category 1 policy, under which the agency generally takes no action against compounders if conditions are met, does not apply to it [2]. On FDA's list for outsourcing facilities, updated 21 March 2025, it sits in category 3, 'nominated without adequate support' [5]. These listings do not by themselves establish whether a particular preparation is lawful in Missouri.
FDA also publishes a page on bulk substances that may present significant safety risks. Thymosin alpha-1 is now in the 'nominated but withdrawn' table, having come off category 2 when the nominators withdrew, and FDA's stated concerns remain posted: 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterisation problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [7].
What did FDA's advisers and HHS decide?
FDA proposed not adding thymosin alpha-1 to the pharmacy bulks list, and its Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate on 4 December 2024. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access [6].
HHS's October 2026 draft enforcement-discretion policy names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not one of them [3].
What Missouri law adds
The Missouri Board of Pharmacy licenses and regulates pharmacies in the state and publishes a license search for the public [12]. Missouri's telehealth statute, section 191.1145 RSMo, says that in order to treat patients in the state through telehealth, health care providers must be fully licensed to practice in Missouri and are subject to regulation by their respective boards. The section was most recently amended by 2025 S.B. 79, effective 28 August 2025 [4].
So what does that mean for access?
There is no FDA-approved thymosin alpha-1 product in the US [1]. FDA proposed not to add it to the pharmacy bulks list, its advisory committee voted against it, and the HHS draft peptide policy does not include it [6][3]. No FDA or HHS action allowing compounding of thymosin alpha-1 was found.
On the federal rules for compounders, FDA lists a valid patient-specific prescription as one condition for pharmacies compounding under the exemption. FDA says outsourcing facilities may distribute compounded drugs under a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified patient [11]. FDA also says it has investigated many cases of serious patient injury linked to poor-quality compounded drugs [11].
Questions worth asking
Does it work?
A 2026 Cochrane review pooled 10 randomised trials with 1,349 adults, published between 1991 and 2018 in Bangladesh, China, Italy, Korea, Singapore and Taiwan. It found possible lower all-cause mortality with thymosin alpha-1 (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or on liver histology, and a very uncertain effect on hepatitis B-related illness. The reviewers said they are 'not sure' it helps [13].
What does the Zadaxin label say about dosing and warnings?
There is no US-approved dose [1]. The Italian Zadaxin label gives 1.6 mg of powder subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. The same label says not for children, lists pregnancy and breastfeeding as contraindications, and advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1]. That is the Italian label for the finished Zadaxin injection, not a US label, and it does not describe any compounded preparation.
Safety
FDA's search of its adverse-event database on 22 April 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as 'infrequent and mild'; treat that as company-linked data [1].
In the 2026 Cochrane review of hepatitis B trials, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [13].
Is it banned in sport?
Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [8]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 in S2.3, under growth factors, which is a different peptide [8].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in Missouri?
Can a Missouri compounding pharmacy make it from bulk powder?
Is thymosin alpha-1 FDA-approved?
Can a clinician licensed in another state prescribe it to a Missouri patient?
What did FDA's advisory committee say about it?
What is the standard dose of thymosin alpha-1?
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Missouri Revisor of Statutes - Revised Statutes of Missouri, RSMo Section 191.1145.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Human Drug Compounding Laws | FDA.
- Board of Pharmacy.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
- Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
- Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.